Electroretinographic responses in epileptic children treated with vigabatrin

J Child Neurol. 2014 Jun;29(6):765-8. doi: 10.1177/0883073813490073. Epub 2013 Jun 6.

Abstract

Vigabatrin is an antiepileptic drug that results in higher gamma-aminobutyrate levels in the brain and retina. Vigabatrin-induced visual field defects are usually asymptomatic and only detectable by perimetry. Further, perimetry requires good cooperation, and children aged under 10 years cannot do it. Electroretinogram response amplitude to full-field 30-Hz flicker shine has been offered to be more specific in predicting visual field defects. This study is scheduled to investigate the vigabatrin-associated visual complications in 67 epileptic children taking vigabatrin using full-field electroretinogram. Electroretinographic surveys showed normal range parameters despite 3 months of vigabatrin treatment, and just 3 (4.47%) children had been visually impaired at the end of 6-month treatment. Among these 3 cases, 1 patient had persistent electroretinogram abnormality despite vigabatrin discontinuation. Our study suggests that vigabatrin is secure for short-term pediatric antiepileptic treatment, with few cases of visual impairments and that are often reversible.

Keywords: electroretinogram; perimetry; vigabatrin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticonvulsants / adverse effects*
  • Child
  • Child, Preschool
  • Electroencephalography
  • Electroretinography
  • Epilepsy / drug therapy
  • Humans
  • Infant
  • Ocular Motility Disorders / chemically induced*
  • Ocular Motility Disorders / diagnosis*
  • Vigabatrin / adverse effects*
  • Visual Field Tests

Substances

  • Anticonvulsants
  • Vigabatrin